SRI-37330

• CAT Number: I042653
• CAS Number: 2322245-42-9
• Molecular Formula: C16H19F3N4O2S
• Molecular Weight: 388.41
• Purity: ≥95%
• Synonyms: N-[[1-[6-(trifluoromethyl)quinazolin-4-yl]piperidin-3-yl]methyl]methanesulfonamide
• InChI: InChI=1S/C16H19F3N4O2S/c1-26(24,25)22-8-11-3-2-6-23(9-11)15-13-7-12(16(17,18)19)4-5-14(13)20-10-21-15/h4-5,7,10-11,22H,2-3,6,8-9H2,1H3
• InChIKey: WRSNFEVXRKOMLL-UHFFFAOYSA-N
• SMILES: CS(=O)(=O)NCC1CCCN(C1)C2=NC=NC3=C2C=C(C=C3)C(F)(F)F

SRI-37330 is an orally active TXNIP inhibitor. SRI-37330 decreases glucagon secretion and action and blocks hepatic glucose output. SRI-37330 can be used in the research of obesity and diabetes[1].
SRI-37330 (1 μM, 24 h) inhibits the activity of the human TXNIP promoter in INS-1 cells[1].
SRI-37330 (1 μM, 24 h) inhibits Mrna and protein levels of TXNIP in INS-1 cells[1].
SRI-37330 (5 μM, 24 h) inhibits polymerase II (Pol II) binding to the E-box motif region of the TXNIP promoter[1].
SRI-37330 (5 μM, 24 h) lowers glucagon secretion in TC1-6 cells[1].
SRI-37330 (0-5 μM, 24 h) inhibits glucagon-induced glucose output from primary hepatocytes[1].
SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) decreases glucagon secretion and action and blocks hepatic glucose output[1].
SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) is well tolerated in male C57BL/6J mice[1].
SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) reverses obesity- and STZ-induced diabetes and hepatic steatosis in mice[1].

Reference

[1]. Thielen LA, et al. Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action. Cell Metab. 2020 Sep 1;32(3):353-365.e8.
 [Content Brief]